Standing Committee discussed the draft law amending and supplementing several articles of the law on technology transfer on ...

An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the retina of mouse models. Neovascularization is a condition that is caused by age ...

Deborah Fuller receives funding from the National Institutes of Health. She is co-founder and a scientific advisor for two biotech companies developing nucleic acid vaccine technologies that are not ...

Ashish K. Jha is dean of Brown University School of Public Health and a contributing Globe Opinion writer. Earlier this month, the Department of Health and Human Services announced it will wind down ...

The United States may be losing its edge in mRNA technology­­. The technology, which powered life-saving COVID-19 vaccines and is now rocketing new cancer therapeutics forward, will soon undergo a ...

The quest for a vaccine against HIV has been going on for about 40 years — almost as long as the virus that causes AIDS has been known to scientists and the public. There has been some progress ...

Rick Bright, the former director of the Biomedical Advanced Research and Development Authority (BARDA) has warned that Department of Health and Human Services' decision to cut funding for mRNA vaccine ...

Dr. Bright is a virologist and a former head of the Biomedical Advanced Research and Development Authority. In early 2020, when the first genetic sequence of the new coronavirus was posted online, ...

They’re turning their backs on a technology thought to have saved millions of lives—with the potential to save many more. This time five years ago, we were in the throes of the covid-19 pandemic. By ...

National Institutes of Health (NIH) Director Jay Bhattacharya claims the federal government recently canceled millions of dollars’ worth of mRNA research contracts because the general public does not ...

After the Department of Health and Human Services canceled about $500 million in funding for mRNA vaccine development, one senior agency leader has decided to call it quits. Alastair Thomson is ...

Settlement reached over mRNA-based COVID vaccines CureVac and GSK get $740 million upfront, and royalties BioNTech's deal to buy CureVac on track GSK's own lawsuits against Pfizer, BioNTech unaffected ...